Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer
V. Quaranta, C. Rainer, S. R. Nielsen, M. Raymant, M. S. Ahmed, D. Engle, A. Taylor, T. Murray, F. Campbell, D. Palmer, D. Tuveson, A. Mielgo, M. Schmid
Abstract
The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumour microenvironment that suppresses and/or excludes cytotoxic CD8+ T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immuno-protective role of the metastatic tumour microenvironment in pancreatic cancer is not completely understood. In this study we find that macrophage-derived granulin contributes to cytotoxic CD8+ T cell exclusion in metastatic livers. Mechanistically, we find that granulin expression by macrophages is induced in response to colony stimulating factor-1. Genetic depletion of granulin reduces the formation a fibrotic stroma, thereby allowing T cell entry at the metastatic site. While metastatic PDAC tumours are largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin depleted tumours restored the anti-tumour immune defence and dramatically decreased metastatic tumour burden. These findings suggest that targeting granulin may serve as a potential therapeutic strategy to restore CD8+ T cell infiltration in metastatic PDAC, thereby converting PDAC metastatic tumours, which are refractory to immune checkpoint inhibitors, into tumours that respond to immune checkpoint inhibition therapies.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression
P. F. Cheung, J. Yang, … J. T. Siveke·bioRxiv·Feb 24, 2021
- Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer
Jennifer L. Hope, Yijuan Zhang, … Linda M. Bradley·bioRxiv·May 22, 2025
- A macrophage-derived noncanonical WNT niche drives immune exclusion in pancreatic cancer
Na Hyun Kim, Young Min Song, … Yi Rang Na·bioRxiv·Feb 9, 2026
- Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer
K. K. Mahadevan, A. M. Dyevoich, … R. Kalluri·bioRxiv·Mar 5, 2023
- Interleukin 6 drives durable T cell-mediated immunity to pancreatic cancer
Paige C. Arneson‐Wissink, Alexandra Q. Bartlett, … Aaron J. Grossberg·Cellular and Molecular Gastroenterology and HepatologyPeer-reviewed·Jan 1, 2026
- Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
R. Ajina, A. Zuo, … L. M. Weiner·bioRxiv·Jun 15, 2020